$GPGI

Leon Cooperman expressed a negative market view due to rising fiscal deficit and debt, citing Warren Buffett's analogy of investors acting like 'Pavlov's dogs'. Omega Advisors, managed by Cooperman, revealed new positions in Amrize AG (AMRZ) and GPGI (GPGI). Amrize reported Q2 revenue growth but missed EBITDA expectations, with RBC downgrading the stock to underperform. Management expects pricing to align with costs by Q4.

GPGI, Inc. (GPGI) reported Q2 2026 results on an earnings call. Pro forma adjusted net sales were $473.2 million, down 4%, and pro forma adjusted EBITDA was $113.9 million, down 13%, with margin at 24.1%. GAAP net income was $50.3 million. FY2026 guidance: revenue $1.95B-$2.1B, adjusted EBITDA $550M-$610M, and free cash flow $275M-$325M.

GPGI, Inc. (GPGI) filed an SEC Form 8-K — Results of Operations and Financial Condition. 1 News Release GPGI Reports Second Quarter 2026 Results ▪ CompoSecure delivers record ROS-enabled results ▪ Husky performance in line with expectations ▪ ROS deployment accelerating at both companies ▪ Progress across the platform – reiterating full year 2026 guidance Second Quar

Knott Thomas R. (See remarks) purchased 85,250 shares of GPGI, Inc. (GPGI) at $11.67 ($0.99M total) on 2026-06-11.

GPGI, Inc. (GPGI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cmpo-20260611 false 0001823144 0001823144 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Moriarty Kevin M purchased 3,956 shares of GPGI, Inc. (GPGI) at $12.64 on 2026-05-26.

Composecure (NYSE:GPGI) saw its shares trade up 4.7% after three insiders purchased additional shares in the company on March 17th. Thomas R. Knott, John D. Cote, and Kurt Schoen collectively acquired shares worth over $900,000. Despite this insider buying activity and the stock's rise, Weiss Ratings initiated a "sell" rating, and MarketBeat shows a consensus "Sell" rating for Composecure.

Composecure Director John Cote purchased 5,800 shares of the company's stock for $17.10 per share, totaling $99,180. The stock rose 4.7% to $18.09 on Wednesday despite below-average trading volume. Composecure topped earnings expectations but has a negative net margin and a consensus "Sell" rating from analysts.